Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. (Nasdaq: IFRX) is a biopharmaceutical company that regularly issues news on its clinical programs targeting the complement system, particularly the C5a/C5aR axis. Company updates highlight progress with its oral C5a receptor inhibitor izicopan (also referenced as INF904) and its intravenously delivered anti-C5a monoclonal antibody vilobelimab, including GOHIBIC (vilobelimab) for SARS-CoV-2-induced acute respiratory distress syndrome in the European Union.
News about InflaRx often covers clinical trial milestones, such as Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria for izicopan, as well as analyses of Phase 3 data for vilobelimab in pyoderma gangrenosum. Releases also describe regulatory interactions, including anticipated discussions with the U.S. Food and Drug Administration, and strategic decisions about prioritizing resources toward izicopan and adjusting spending on GOHIBIC (vilobelimab).
Investors following IFRX news can expect announcements on clinical data readouts, participation in healthcare and investor conferences, and business updates related to funding, cash runway and partnering activities. InflaRx’s communications have included information on BARDA-supported studies in acute respiratory distress syndrome, co-development activities for an anti-C5a antibody in China, and notices regarding Nasdaq listing requirements.
This news feed aggregates InflaRx’s press releases and related coverage so readers can review clinical developments, regulatory updates and corporate actions in one place. For those tracking complement-targeted therapeutics, IFRX news provides insight into how the company is advancing its C5a and C5aR inhibitor programs across dermatologic and respiratory indications and how it is aligning its strategy and capital allocation with these priorities.
InflaRx (Nasdaq: IFRX) will participate in the Raymond James 2026 Biotech Innovation Symposium in New York on April 14, 2026. The company will hold one-on-one investor meetings and present its pipeline highlights, including izicopan and vilobelimab, and corporate overview.
Contact details for investor relations and media are provided.
InflaRx (Nasdaq: IFRX) presented Phase 3 vilobelimab data for pyoderma gangrenosum at the 2026 AAD Annual Meeting (March 27-31, 2026). The trial enrolled 54 patients and was stopped early for futility. Results showed higher complete remission and ulcer-closure rates, strong C5a suppression (-76.6% vs -13.5%), and a generally favorable safety profile.
The company plans FDA discussions on a PG development path and expects future PG work likely with a partner.
InflaRx (Nasdaq: IFRX) reported full‑year 2025 results and highlighted positive Phase 2a data for oral C5aR inhibitor izicopan, prioritizing hidradenitis suppurativa (HS) and discussing Phase 2b design with the FDA. Cash and marketable securities totaled €46.2 million, funding operations to mid‑2027.
Company plans a China PK bridging study, ongoing collaborator discussions, and a virtual Capital Markets Day this spring.
InflaRx (Nasdaq: IFRX) announced a late-breaking oral presentation of Phase 3 vilobelimab results in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting in Denver, March 27-31, 2026.
The oral session is scheduled for March 28, 2026, 2:24-2:36 PM MT, presenter Benjamin Kaffenberger, MD. The company also highlights its izicopan program and anti-C5a/C5aR platform.
InflaRx (Nasdaq: IFRX) will report fourth quarter and full year 2025 results on March 19, 2026 before the market opens; no conference call is planned.
The company is developing izicopan (INF904), an oral C5aR inhibitor, and vilobelimab, an IV anti-C5a antibody, and maintains offices in Jena, Munich and Ann Arbor.
InflaRx (Nasdaq: IFRX) will participate in the Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026, with a fireside chat on March 9 at 9:20 AM ET and one-on-one investor meetings the same day.
Live streaming and replay of the fireside chat will be available via a company link; investor relations contacts are provided for meeting requests.
InflaRx (Nasdaq: IFRX) will participate in investor conferences in February 2026, offering live presentations and one-on-one meetings. Key appearances include a fireside chat at the Guggenheim Biotech Summit on Feb 11, 2026 at 11:30 AM ET and a virtual presentation at Oppenheimer on Feb 25, 2026 at 8:40 AM ET. Replay links and details for one-on-one meetings are available from the company. The release also summarizes InflaRx's lead programs, izicopan and vilobelimab, and corporate locations in Germany and the U.S.
InflaRx (Nasdaq: IFRX) is refocusing resources on its oral C5aR inhibitor izicopan, aiming for Phase 2b readiness in hidradenitis suppurativa (HS) and broader inflammation & immunology (I&I) indications. The company is initiating a PK bridging study in China in 2026 to enable expedited PoC studies and is pursuing partner discussions to accelerate development. InflaRx is executing an ~30% workforce reduction, expects a one-time charge of ~$7 million, and says the actions extend its cash runway to mid-2027. A virtual Capital Markets Day is planned for spring 2026.
InflaRx (Nasdaq: IFRX) provided updated analyses from its terminated Phase 3 study of vilobelimab in ulcerative pyoderma gangrenosum (PG). The trial was stopped early for futility after enrolling 54 patients (30 completed 6 months). The prespecified primary endpoint (complete target ulcer closure on two consecutive visits) favored vilobelimab 20.8% vs placebo 16.7% (p=NS). Post-hoc analyses showed statistically significant reductions in target ulcer volume: MMRM percent change overall -45.4% (p=0.0428) and weekly differences from Week 14 to 26 (e.g., Week 26 -63.2%, p=0.0122); ANCOVAs for volume and area were p=0.0111 and p=0.0072. Safety was generally well tolerated with similar serious related TEAEs (6.3% vs 4.5%). InflaRx plans FDA discussions and expects future PG work would require a partner.
InflaRx (Nasdaq: IFRX) announced the World Health Organization has granted the international nonproprietary name izicopan for its oral C5aR inhibitor formerly known as INF904; the name will be published in the WHO recommended INN list.
Izicopan has shown tolerability in first‑in‑human single doses (3–240 mg) and multiple doses (30 mg once daily to 90 mg twice daily), pharmacokinetic/pharmacodynamic support with a ≥90% blockade of C5a‑induced neutrophil activation over 14 days, and topline Phase 2a signals of clinical activity in hidradenitis suppurativa and chronic spontaneous urticaria.